All In Biotech

NDA 019264 · Fresenius Kabi USA

Pentam

Pentamidine Isethionate · Injection

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Jan 8, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1984

Oct 16, 1984

Approved uses

1

Original approval plus efficacy supplements

Registered trials

48

13 Phase 3, 2 recruiting

FAERS reports

1,115

1,019 serious, 201 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 13, 2022.

INDICATIONS AND USAGE Pentam 300 (pentamidine isethionate for injection) is indicated for the treatment of pneumonia due to Pneumocystis carinii .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 16, 1984 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • PENTAM · PENTAMIDINE ISETHIONATE 300MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Pentamidine Isethionate" as an intervention, any sponsor and status, largest first.

All 48 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia133
  • pyrexia126
  • off label use87
  • aplastic anaemia77
  • neutropenia73
  • diarrhoea72
  • mucosal inflammation57
  • pneumonia57
  • sepsis54
  • pancytopenia52
  • dyspnoea48
  • nausea48

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200411
200519
200645
200745
200838
200964
2010107
201161
201251
201325
201412
201516
201635
201723
201824
201949
202069
202189
202295
202338
202490
202569
202640

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 27 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.